Portage Biotech stock soars on promising preclinical data

Published 27/03/2025, 21:40
© Reuters.

Investing.com -- Shares of Portage Biotech Inc. (NASDAQ: PRTG) surged 29% following the presentation of new preclinical data for its mesothelioma treatment, PORT-7. The company unveiled these findings at the European Lung Cancer Congress in Paris, which took place from March 26-29.

Portage Biotech’s recent data indicates that PORT-7, a selective Adenosine A2B receptor inhibitor, not only shows single-agent activity but also achieves over 90% inhibition of tumor growth when used in conjunction with an anti-PD1 antibody in a mesothelioma murine model. Furthermore, the study revealed significant infiltration of immune effector cells in the tumors. Mesothelioma, a particularly aggressive form of cancer with few existing treatment options, could potentially benefit from this novel approach to immunotherapy.

The company is also progressing with the dose escalation of PORT-6, another promising compound designed to inhibit the A2A adenosine receptor. Portage Biotech aims to combine PORT-6 with PORT-7 in a clinical trial to create a comprehensive blockade of adenosine-induced immunosuppression within the tumor microenvironment. This strategy is intended to enhance the immune system’s response to tumors and improve the efficacy of immunotherapy for solid tumors.

The enthusiasm surrounding Portage Biotech’s stock can be attributed to the promising implications of these preclinical results, suggesting a potential advancement in treatment for mesothelioma patients.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.